Vitae Pharmaceuticals plans $40 million at-the-market equity offering

Deal arranged with Cantor Fitzgerald; proceeds fund corporate purposes

By Devika Patel

Knoxville, Tenn., June 30 – Vitae Pharmaceuticals, Inc. negotiated a $40 million at-the-market equity offering with agent Cantor Fitzgerald & Co. on June 21, according to a prospectus supplement and 8-K filed Tuesday with the Securities and Exchange Commission.

Cantor will be paid a 3% commission.

Proceeds will be used for general corporate purposes.

The clinical-stage biotechnology company is based in Fort Washington, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.